Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;36(4):745-768.
doi: 10.1016/j.hoc.2022.03.007. Epub 2022 Jun 27.

Gene-Based Natural Killer Cell Therapies for the Treatment of Pediatric Hematologic Malignancies

Ruyan Rahnama  1 , Ilias Christodoulou  2 , Challice L Bonifant  3
Affiliations
Review

Gene-Based Natural Killer Cell Therapies for the Treatment of Pediatric Hematologic Malignancies

Ruyan Rahnama et al. Hematol Oncol Clin North Am. 2022 Aug.

Abstract

Pediatric blood cancers are among the most common malignancies that afflict children. Intensive chemotherapy is not curative in many cases, and novel therapies are urgently needed. NK cells hold promise for use as immunotherapeutic effectors due to their favorable safety profile, intrinsic cytotoxic properties, and potential for genetic modification that can enhance specificity and killing potential. NK cells can be engineered to express CARs targeting tumor-specific antigens, to downregulate inhibitory and regulatory signals, to secrete cytokine, and to optimize interaction with small molecule engagers. Understanding NK cell biology is key to designing immunotherapy for clinical translation.

Keywords: Blood cancer; Genetic engineering; Immunotherapy; NK cell.

PubMed Disclaimer

Conflict of interest statement

Disclosure C.L. Bonifant and I. Christodoulou have pending patent applications describing the use of CAR-NK cells as therapeutics. C.L. Bonifant and I. Christodoulou have received research support from Merck Sharp and Dohme, Bristol-Myers Squibb, and Kiadis Pharma.

Figures

Fig. 1.
Fig. 1.
Methods of Genetic Engineering in NK Cells. (A) Viral-mediated, including γ-retroviral and lentiviral vectors. (B) Nonviral mediated, including electroporation, Charge-altering releasable transporters, and transposon systems. (C) Targeted knockdown and knock-in, including zinc-finger nucleases (ZFN), transcription activator-like nucleases (TALENs), and CRISPR/Cas9 systems as NK cell engineering methods.
Fig. 2.
Fig. 2.
NK Cell Engineering for Therapeutic Application. Schematic depicting (A) Expression of CARs targeting TAA to enhance cytotoxicity and NK cell activation. (B) Constitutive secretion or (C) membrane-tethered cytokine can sustain NK cell activation and persistence. (D) Enhanced surface expression of chemokine receptors can mediate NK cell localization to tumor along chemokine gradients. (E) Engager molecules (BiKEs or TriKEs) can be combined with engineered CD16 to direct powerful ADCC of tumor cells. Incorporation of IL15 in the small molecule can further support persistence.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Madhusoodhan PP, Carroll WL, Bhatla T. Progress and prospects in pediatric leukemia. Curr Probl Pediatr Adolesc Health Care 2016;46(7):229–41. - PubMed
    1. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics. CA Cancer J Clin 2014;64(2):83–103. - PubMed
    1. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a children’s oncology group report. Leukemia 2010;24(2):285–97. - PMC - PubMed
    1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia. N Engl J Med 2018;378(5):439–48. - PMC - PubMed
    1. O’Leary MC, Lu X, Huang Y, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory b-cell precursor acute lymphoblastic leukemia. Clin Cancer Res 2019;25(4):1142–6. - PubMed

Publication types